Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way - GBI Research Reports

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way - GBI Research Reports
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way
Published Sep 01, 2016
70 pages — Published Sep 01, 2016
Price US$ 6,995.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. Ophthalmology encompasses a diverse range of indications affecting this system. Key diseases within this therapy area include glaucoma, age-related macular degeneration, diabetic macular edema, diabetic retinopathy and dry eye syndrome.

While treatments for dry eye syndrome are generally able to control its symptoms in the majority of patients, the other four diseases are progressive, chronic, incurable and can lead to visual impairment and even blindness if not adequately treated. Treatment is aimed at managing the disease, in order to reduce the severity of symptoms and to slow progression, rather than being curative.

Scientific advancements over recent decades have revealed a broad range of novel potential molecular targets, enabling progress in a previously stagnant field. This is reflected by the high number of products in development, with 782 pipeline products currently in the ophthalmology therapy area pipeline.

Moreover, there are a total of 158 first-in-class pipeline products in development for ophthalmology indications, representing 36% of the 438 pipeline products for which there is a disclosed molecular target. They appear generally promising in terms of safety and efficacy, and appear to have significant potential to strengthen the treatment landscape for key ophthalmological conditions - as well as representing promising commercial opportunities.

Many first-in-class products in the current ophthalmology pipeline have previously been involved in licensing and co-development deals. This indicates a strong degree of strategic consolidation uptake for first-in-class products in ophthalmology, and a willingness on the part of companies to invest in innovative products that show promise in both preclinical and clinical trials.

Scope

- Analysis of innovation in the ophthalmology markets in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape surrounding first-in-class products in ophthalmology, and highlights opportunities for in-licensing. Key indications covered in detail include glaucoma, age-related macular degeneration, diabetic retinopathy and diabetic macular edema.
- A brief introduction to ophthalmology, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for ophthalmology therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the ophthalmology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the ophthalmology pipeline, stratified by indication, stage of development, molecule type and

  
Source:
Document ID
GBIHC411MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures32
Executive Summary51
  Market Landscape Poised for Entry of Novel Products51
  Moderately-Sized but Strong First-in-Class Pipeline51
  Strong Uptake of First-in-Class Products in Strategic Consolidations51
The Case for Innovation63
  Growing Opportunities for Biologic Products71
  Diversification of Molecular Targets71
  Innovative First-in-Class Product Development Remains Attractive71
  Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation81
  Sustained Innovation81
Clinical and Commercial Landscape913
  Therapy Area Overview91
    Glaucoma91
    Age-related Macular Degeneration91
    Diabetic Macular Edema91
    Diabetic Retinopathy91
    Dry Eye Syndrome101
  Disease Symptoms102
  Epidemiology and Etiology121
    Glaucoma121
    Age-related Macular Degeneration121
    Diabetic Retinopathy and Diabetic Macular Edema121
    Dry Eye Syndrome121
  Diagnosis131
  Pathophysiology131
    Healthy Eye Physiology131
    Glaucoma141
    Age-related Macular Edema151
    Diabetic Macular Edema and Diabetic Retinopathy161
  Treatment Options172
  Prognosis191
    Glaucoma191
    Age-Related Macular Degeneration191
    Diabetic Retinopathy and Diabetic Macular Edema191
    Dry Eye Syndrome201
  Overview of Marketed Products in Ophthalmology201
    Molecule Type and Target Analysis202
Assessment of Pipeline Product Innovation2213
  Ophthalmology Pipeline by Molecular Target253
  Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family281
  First-in-Class Pipeline Programs Targeting Novel Molecular Targets287
Signaling Network, Disease Causation and Innovation Alignment354
  Complexity of Signaling Networks in Ophthalmology351
  First-in-Class Matrix Assessment354
First-in-Class Target Evaluation3911
  Pipeline Programs Targeting RPE65 and RBP4392
  Pipeline Programs Targeting Eotaxin-1 and CCR3412
  Pipeline Programs Targeting LRP6431
  Pipeline Programs Targeting TGF-Beta 2441
  Pipeline Programs Targeting NGF, and LNGFR and TrkA Nerve Growth Factor Receptors453
  Pipeline Programs Targeting Serine Protease HtrA1481
  Conclusion491
Deals and Strategic Consolidations5013
  Industry-Wide First-in-Class Deals501
  Licensing Deals512
    Licensing Deals by Molecule Type531
    Licensing Deals by Molecular Target532
    Licensing Deals Valued Above $100m551
  Co-development Deals561
    Co-development Deals by Molecule Type571
    Co-development Deals by Molecular Target572
    Co-development Deals Valued Above $100m591
  First-in-Class Programs Not Involved in Licensing or Co-development Deals603
Appendix638
  Abbreviations631
  References635
  Research Methodology681
  Secondary Research692
    Market Analysis691
    Pipeline Analysis691
      Overall Pipeline691
      First-in-Class Analysis691
    First-in-Class Matrix Assessment691
    First-in-Class Target Profiles701
    Licensing and Co-development Deals701
  Contact Us701
  Disclaimer701

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way" Sep 01, 2016. Alacra Store. Mar 28, 2024. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Frontier-Pharma-Ophthalmology-Therapeutics-Advancements-in-Disease-Understanding-Pave-Way-for-Increasingly-Diverse-Therapeutic-Options-with-Age-Related-Macular-Degeneration-and-Glaucoma-Leading-the-Way-2115-737>
  
APA:
GBI Research Reports. (2016). Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way Sep 01, 2016. New York, NY: Alacra Store. Retrieved Mar 28, 2024 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Frontier-Pharma-Ophthalmology-Therapeutics-Advancements-in-Disease-Understanding-Pave-Way-for-Increasingly-Diverse-Therapeutic-Options-with-Age-Related-Macular-Degeneration-and-Glaucoma-Leading-the-Way-2115-737>
  
US$ 6,995.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.